Loading
NYSEHealthcareDrug Manufacturers - General
Latest quote
$143.78
+$0.67 · +0.47%
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Regular session
$143.78
+$0.67 · +0.47%
Regular session · ET · Market data may be delayed.
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Day range
Current $143.78
52-week range
Current $143.78
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
86
Deep Value
Sentiment
51
Mixed
Risk
22
Moderate Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Day range
Current $143.78
52-week range
Current $143.78
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 54.81B USD | 51.72B USD | 46.66B USD | 43.46B USD | 43.97B USD |
| Cost of goods sold | 13.69B USD | 12.83B USD | 12.47B USD | 11.58B USD | 11.74B USD |
| Gross profit | 41.12B USD | 38.9B USD | 34.19B USD | 31.88B USD | 32.24B USD |
| Research and development | 10.74B USD | 10.02B USD | 11.37B USD | 9.17B USD | 8.64B USD |
| Selling, general, and administrative | 13.31B USD | 12.57B USD | 12.52B USD | 12.19B USD | 12.83B USD |
| Operating expenses | 24.05B USD | 24.35B USD | 24.42B USD | 23.93B USD | 22.18B USD |
| Interest income | 374.91M USD | 567.68M USD | 629.24M USD | 377.74M USD | 71M USD |
| Interest expense | 1.19B USD | 1.04B USD | 876.12M USD | 834.62M USD | 905M USD |
| Depreciation and amortization | 5.35B USD | 6.07B USD | 8.28B USD | 6.71B USD | 5.6B USD |
| Operating income | 17.07B USD | 14.54B USD | 9.77B USD | 7.95B USD | 10.06B USD |
| Net income | 14.06B USD | 11.94B USD | 14.85B USD | 6.96B USD | 24.02B USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$146
1.54% upsideCash distributions grouped by calendar year; partial years are marked.
$3.994
2025 complete year+24.8% since 2021
2026 partial: $4.7403
$3.1991
2,021
$3.3253
2,022
$3.4987
2,023
$3.1986
2,024
$3.994
2,025
$4.7403
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 11, 2026 | $4.7403Annual | Mar 11, 2026 | Mar 16, 2026 |
Dividend | Mar 12, 2025 | $3.994Annual | Mar 12, 2025 | Apr 25, 2025 |
Dividend | Mar 7, 2024 | $3.1986Annual | Mar 8, 2024 | Apr 19, 2024 |
Dividend | Mar 9, 2023 | $3.4987Annual | Mar 10, 2023 | Mar 20, 2023 |
Dividend | Mar 8, 2022 | $3.3253Annual | Mar 9, 2022 | Mar 17, 2022 |
Dividend | Mar 4, 2021 | $3.1991Annual | Mar 5, 2021 | Mar 15, 2021 |
Ex-dividend Mar 11, 2026
$4.7403
Annual
Record Mar 11, 2026 · Payment Mar 16, 2026
Ex-dividend Mar 12, 2025
$3.994
Annual
Record Mar 12, 2025 · Payment Apr 25, 2025
Ex-dividend Mar 7, 2024
$3.1986
Annual
Record Mar 8, 2024 · Payment Apr 19, 2024
Ex-dividend Mar 9, 2023
$3.4987
Annual
Record Mar 10, 2023 · Payment Mar 20, 2023
Ex-dividend Mar 8, 2022
$3.3253
Annual
Record Mar 9, 2022 · Payment Mar 17, 2022
Ex-dividend Mar 4, 2021
$3.1991
Annual
Record Mar 5, 2021 · Payment Mar 15, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - International Value ETFDFIV127.36M0.60%21.3B USD0.27%$55.35+0.13%
Dimensional - International Core Equity Market ETFDFAI111.58M0.63%17.65B USD0.18%$41.265+0.47%
Dimensional - International Core Equity 2 ETFDFIC103.4M0.69%14.92B USD0.22%$37.455+0.44%
Avantis International Equity ETFAVDE88.4M0.46%19.06B USD0.23%$89.635+0.40%
Dimensional International High Profitability ETFDIHP84.24M1.32%6.39B USD0.27%$33.895+0.61%
Dimensional World ex U.S. Core Equity 2 ETFDFAX74.23M0.60%12.26B USD0.28%$37.005+0.56%
Fidelity Enhanced International ETFFENI50.24M0.44%11.47B USD0.28%$39.655+0.34%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH42.93M4.13%1.04B USD0.13%$28.38+1.48%Dimensional - International Value ETFDFIVDimensional - International Core Equity Market ETFDFAIDimensional - International Core Equity 2 ETFDFICAvantis International Equity ETFAVDEDimensional International High Profitability ETFDIHPDimensional World ex U.S. Core Equity 2 ETFDFAXFidelity Enhanced International ETFFENIPortfolio Building Block World Pharma and Biotech Index ETFPBPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
